Baird Reiterates Outperform Rating on Reata Pharmaceuticals (RETA) Following Announced Deal with Blackstone
Tweet Send to a Friend
Baird analyst Brian Skorney reiterated an Outperform rating and $268.00 price target on Reata Pharmaceuticals (NASDAQ: RETA) following the company's ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
